Header Logo

Connection

KENNETH MCCLAIN to Female

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Female.
KENNETH MCCLAIN
Connection Strength
0.501
Female
  1. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.025
  2. Management of severe pulmonary Langerhans cell histiocytosis in children. Pediatr Pulmonol. 2020 08; 55(8):2074-2081.
    View in: PubMed
    Score: 0.025
  3. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.022
  4. Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
    View in: PubMed
    Score: 0.022
  5. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.021
  6. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr. 2017 10; 189:72-78.e3.
    View in: PubMed
    Score: 0.020
  7. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.019
  8. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.017
  9. fHLH: becoming a blended family. Blood. 2014 Aug 21; 124(8):1210-1.
    View in: PubMed
    Score: 0.016
  10. Why do T cells cause so much trouble? Blood. 2014 Mar 27; 123(13):1978.
    View in: PubMed
    Score: 0.016
  11. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14; 8:72.
    View in: PubMed
    Score: 0.015
  12. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.014
  13. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011 Jan; 56(1):154-5.
    View in: PubMed
    Score: 0.013
  14. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer. 2010 Mar; 54(3):424-8.
    View in: PubMed
    Score: 0.012
  15. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
    View in: PubMed
    Score: 0.011
  16. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Jun; 50(6):1227-35.
    View in: PubMed
    Score: 0.011
  17. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer. 2008 Mar; 50(3):728-30.
    View in: PubMed
    Score: 0.010
  18. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.010
  19. Intracranial plasma cell granuloma: case report and treatment of recurrence with methotrexate and 6-mercaptopurine. J Pediatr Hematol Oncol. 2005 Nov; 27(11):599-603.
    View in: PubMed
    Score: 0.009
  20. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10; 146(2):206-218.
    View in: PubMed
    Score: 0.009
  21. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.008
  22. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.008
  23. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.008
  24. Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS. AJNR Am J Neuroradiol. 2022 11; 43(11):1667-1673.
    View in: PubMed
    Score: 0.007
  25. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.007
  26. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol. 2021 02; 192(3):667-671.
    View in: PubMed
    Score: 0.006
  27. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
    View in: PubMed
    Score: 0.006
  28. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.006
  29. A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019 08; 66(8):e27798.
    View in: PubMed
    Score: 0.006
  30. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018 10; 19(10):e522-e530.
    View in: PubMed
    Score: 0.005
  31. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.005
  32. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.005
  33. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol. 1998 Mar; 30(3):175-7.
    View in: PubMed
    Score: 0.005
  34. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 12 21; 130(25):2728-2738.
    View in: PubMed
    Score: 0.005
  35. PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT. Clin Nucl Med. 2017 Aug; 42(8):582-588.
    View in: PubMed
    Score: 0.005
  36. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
    View in: PubMed
    Score: 0.005
  37. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.005
  38. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.005
  39. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.005
  40. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.005
  41. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.005
  42. A 2-year-old with 4 weeks of daily fever. Pediatrics. 2015 May; 135(5):902-8.
    View in: PubMed
    Score: 0.004
  43. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015 Jan 22; 125(4):591-9.
    View in: PubMed
    Score: 0.004
  44. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.004
  45. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014; 7(9):6225-30.
    View in: PubMed
    Score: 0.004
  46. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.004
  47. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol. 2014 Apr; 31(3):253-7.
    View in: PubMed
    Score: 0.004
  48. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.004
  49. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62.
    View in: PubMed
    Score: 0.004
  50. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20; 121(25):5006-14.
    View in: PubMed
    Score: 0.004
  51. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.004
  52. Infection-associated hemophagocytic syndrome. Evidence for Epstein-Barr virus gene expression. Am J Pediatr Hematol Oncol. 1991; 13(4):476-81.
    View in: PubMed
    Score: 0.003
  53. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008 Nov; 153(5):700-5, 705.e1-2.
    View in: PubMed
    Score: 0.003
  54. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep; 48(9):1971-80.
    View in: PubMed
    Score: 0.003
  55. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Feb; 50(2):381-3.
    View in: PubMed
    Score: 0.003
  56. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J. 2003 Jul; 22(7):663-6.
    View in: PubMed
    Score: 0.002
  57. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003 May 14; 289(18):2393-9.
    View in: PubMed
    Score: 0.002
  58. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003 Feb 01; 36(3):306-12.
    View in: PubMed
    Score: 0.002
  59. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.002
  60. Human herpesvirus 6 and cytomegalovirus infections in children with human immunodeficiency virus infection and cancer. Pediatr Infect Dis J. 2002 Feb; 21(2):125-32.
    View in: PubMed
    Score: 0.002
  61. Acquired immune deficiency, myelodysplasia, and acute nonlymphocytic leukemia associated with monosomy 7 and t(3;3) (q21;q26) in a child with Langerhans cell histiocytosis. Am J Pediatr Hematol Oncol. 1989; 11(2):153-7.
    View in: PubMed
    Score: 0.001
  62. Successful outcome of severe aplastic anemia following Epstein-Barr virus infection. Am J Hematol. 1988 Aug; 28(4):273-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.